EGFR, the Lazarus target for precision oncology in glioblastoma
| Autor: | Benjamin Lin, Julia Ziebro, Erin Smithberger, Kasey R Skinner, Eva Zhao, Timothy F Cloughesy, Zev A Binder, Donald M O’Rourke, David A Nathanson, Frank B Furnari, C Ryan Miller |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Neuro-Oncology. 24:2035-2062 |
| ISSN: | 1523-5866 1522-8517 |
| DOI: | 10.1093/neuonc/noac204 |
| Popis: | The Lazarus effect is a rare condition that happens when someone seemingly dead shows signs of life. The epidermal growth factor receptor (EGFR) represents a target in the fatal neoplasm glioblastoma (GBM) that through a series of negative clinical trials has prompted a vocal subset of the neuro-oncology community to declare this target dead. However, an argument can be made that the core tenets of precision oncology were overlooked in the initial clinical enthusiasm over EGFR as a therapeutic target in GBM. Namely, the wrong drugs were tested on the wrong patients at the wrong time. Furthermore, new insights into the biology of EGFR in GBM vis-à-vis other EGFR-driven neoplasms, such as non-small cell lung cancer, and development of novel GBM-specific EGFR therapeutics resurrects this target for future studies. Here, we will examine the distinct EGFR biology in GBM, how it exacerbates the challenge of treating a CNS neoplasm, how these unique challenges have influenced past and present EGFR-targeted therapeutic design and clinical trials, and what adjustments are needed to therapeutically exploit EGFR in this devastating disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|